Revance Therapeutics, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (36)

Latest Posts

About This Stock More About This Stock
Revance, Amphastar Named Top 2020 Specialty Pharmaceuticals Ideas At Wells Fargo
Article By: The Fly
Wednesday, January 22, 2020 8:21 AM EDT
Wells Fargo analyst Jacob Hughes named Revance Therapeutics and Amphastar Pharmaceuticals his top ideas for 2020 in the Specialty Pharmaceuticals space.
In this article: AMPH, RVNC Also: AGN, EBS, JAZZ, PRGO, TEVA, MNK, BHC, OSMT, KRTX
Read
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Article By: ChinaBio® Today
Saturday, December 8, 2018 4:21 PM EDT
WuXi AppTec, China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range (see story). In May, WuXi became a public company by completing a $328 million IPO in Shanghai.
In this article: RVNC, VBIV, CASI, SPPI
Read
Revance Fails Phase 3 Trial; Shares Down 24% In After-Hours
Article By: Terry Chrisomalis
Tuesday, June 14, 2016 3:10 AM EDT
The phase 3 trial was using the company's drug RT001 to treat patients with lateral canthal lines, or Crows Feet. The drug in question is a topical gel that would be easier to administer in areas of the body that are very sensitive.
In this article: RVNC
Read
Five Biotech Stocks That Doubled In 2015
Article By: Zacks Investment Research
Friday, January 8, 2016 5:10 AM EDT
It’s been a roller-coaster ride for the biotech sector in 2015, with several stocks seeing major highs and lows as the year progressed. The year will continue to see mergers and acquisitions and licensing and collaboration deals being signed.
In this article: LGND, EXEL, SRPT, HRTX, RVNC Also: AMGN, ABBV
Read
Revance Announces Positive Phase 2 Results In Anti-Wrinkle Study
Article By: Terry Chrisomalis
Thursday, October 29, 2015 2:29 PM EDT
Revance announces positive phase 2 results in anti-wrinkle study; Shares are up 30%.
In this article: RVNC
Read

Latest Tweets for $RVNC

No tweets yet!

PARTNER HEADLINES